Modalis Therapeutics (モダリス, formerly Eddie Gene) is a biotech company developing therapeutic drugs through epigenetic gene modulation. It utilizes a CRISPR-GNDM genome editing platform, which enables the locus-specific modulation of gene expression or histone modification without the need for double-stranded DNA cleavage, gene editing, or base editing. The company focuses on genetic disorders caused by loss of gene regulation.